Radiation Oncology Market and the Shift Toward Intelligent Oncology Systems

Radiotherapy is undergoing a structural transformation driven by multiple converging forces that are reshaping how cancer care is delivered globally. The radiotherapy market is being influenced by rising cancer burden, increasing demand for precision treatments, and continuous innovation in medical technology. Within this shift, four key pointers stand out:

• Rising global cancer incidence, increasing demand for advanced and precise radiation treatment options
• Rapid adoption of artificial intelligence in treatment planning, contouring, and workflow automation
• Expansion of adaptive radiotherapy, enabling real-time treatment plan adjustments based on tumor response and anatomical changes
• Growing preference for minimally invasive, high-precision techniques such as stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT)

These factors are collectively improving treatment accuracy, reducing planning time, and enabling more personalized oncology care. As healthcare systems prioritize efficiency and outcome-based treatment models, radiotherapy is evolving into a highly technology-driven discipline supported by imaging innovation, automation, and advanced dose delivery systems.

The global radiation oncology market size was estimated at USD 14.03 billion in 2025 and is projected to reach USD 33.09 billion by 2033, expanding at a CAGR of 11.42% from 2026 to 2033. This strong growth reflects a broader shift in oncology toward precision-based treatment modalities that improve tumor control while minimizing harm to surrounding healthy tissues. Increasing cancer prevalence, expanding healthcare infrastructure, and rising investment in advanced radiotherapy systems are further strengthening this growth trajectory.

Technology Transformation Reshaping Radiation Oncology

The radiation oncology landscape is being redefined by the convergence of artificial intelligence, advanced imaging systems, and automation technologies. AI is increasingly being used for tumor segmentation, organ-at-risk contouring, and treatment plan optimization, significantly improving speed and consistency while reducing manual variability across clinical workflows. This is allowing radiation oncology departments to handle growing patient volumes more efficiently.

Adaptive radiotherapy is emerging as a major advancement within the radiotherapy market, enabling clinicians to adjust treatment plans during the course of therapy based on changes in tumor size, patient anatomy, or internal motion. This capability is particularly valuable in cancers such as lung, prostate, head and neck, and abdominal tumors, where precision directly impacts clinical outcomes.

Stereotactic techniques such as SRS and SBRT are also gaining strong adoption due to their ability to deliver highly targeted radiation doses in fewer sessions, typically ranging from one to five fractions. This reduces treatment burden for patients while improving clinical throughput and resource utilization in oncology centers.

Proton therapy is another key growth area, supported by its ability to deliver radiation with minimal exit dose, thereby reducing exposure to surrounding healthy tissues. It is especially important in pediatric oncology and tumors located near critical structures. The development of compact proton therapy systems is further improving accessibility and supporting wider adoption across hospitals and specialized cancer centers.

Competitive Landscape and Key Radiation Oncology Companies

The radiotherapy market is supported by a strong and competitive ecosystem of global medical technology companies focused on innovation in precision delivery systems, software integration, and advanced oncology platforms.

Key radiation oncology companies include:

• Varian Medical Systems, Inc. (Siemens Healthineers)
• Elekta AB
• Accuray Incorporated
• IBA (Ion Beam Applications)
• Becton, Dickinson and Company
• Curium
• Panacea Medical Technologies
• Mevion Medical Systems
• Canon Medical Systems Corporation
• Sumitomo Heavy Industries, Ltd.

These companies are actively investing in AI-driven treatment planning, adaptive radiotherapy platforms, compact proton therapy systems, and integrated oncology ecosystems that enhance clinical efficiency and treatment precision.

Recent Developments Accelerating Market Growth

Recent innovations in radiation oncology are significantly shaping the direction of the radiotherapy market and improving clinical capabilities across treatment centers.

• In March 2026, IBA launched myQA MatriXX AiR, the first wireless 2D ionization chamber array designed for fast and efficient patient-specific quality assurance in particle therapy, improving workflow speed and operational efficiency in proton treatment environments.
• In September 2025, Accuray Inc. introduced Accuray Stellar, an integrated hardware and software solution designed to enable automated adaptive radiotherapy workflows, supporting faster treatment adaptation and improved consistency in clinical practice.
• In September 2025, Sumitomo Heavy Industries announced a collaboration with Leo Cancer Care (USA) to develop an upright proton therapy system aimed at improving patient positioning, comfort, and potentially enhancing radiation delivery precision.
• In January 2025, Mevion Medical Systems delivered the first FIT compact proton therapy system to Stanford Health Care, marking an important milestone in expanding access to space-efficient proton therapy solutions.

Outlook: Shift Toward Intelligent and Precision-Driven Radiotherapy

The future of radiation oncology is being shaped by deeper integration of artificial intelligence, real-time adaptive systems, and biologically guided treatment planning. These advancements are enabling more individualized therapy strategies based on tumor behavior and patient-specific response patterns.

At the same time, improvements in compact proton systems, automation technologies, and imaging integration are expanding access to advanced radiotherapy across a wider range of healthcare facilities. This is helping bridge the gap between high-end cancer centers and regional treatment providers.

As these trends continue to evolve, the radiotherapy market is transitioning from equipment-driven growth to an ecosystem-led model, where software intelligence, clinical automation, and precision engineering collectively define treatment outcomes. This positions radiation oncology as a central pillar in the next generation of global cancer care delivery.